Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy
Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 673-683
DOI: 10.1002/cpt.70327 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 13.05.2026. Verfasst von Catherine M E de Cuba und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Transcranial Magnetic Stimulation, Anticonvulsants, Levetiracetam, Epilepsy, Generalized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision making. Building upon prior transcranial magnetic stimulation (TMS) work in healthy participants, this study aimed to establish TMS‐derived endpoints as translational biomarkers of ASM effects in patients. In a randomized, double‐blind, placebo‐controlled, two‐way crossover design, patients with generalized epilepsy on levetiracetam (500 mg twice daily; n = 14) or valproic acid (≤1,000 mg/day; levetiracetam‐naïve, n = 12) received a single oral dose of levetiracetam (2000 mg) or placebo. Participants were asked to refrain from their morning ASM dose to minimize background ASM levels while maintaining seizure protection. TMS combined with electromyography (EMG) and electroencephalography (EEG), and resting‐state EEG were performed pre‐dose, 1.5 h, and 3 h post‐dose. Outcomes were analyzed using mixed‐effects analysis of covariance or cluster‐based permutation testing. Levetiracetam significantly reduced motor‐evoked potential (MEP) amplitude, enhanced long‐interval intracortical inhibition (LICI), and increased frontal gamma and beta power, with larger effect sizes in levetiracetam‐naïve patients. These findings were further supported by linear concentration–response relationships for these endpoints. TMS–EEG revealed group‐specific modulation: early TMS‐evoked potential components (P30/N45) in levetiracetam patients vs. later components (N100/P180) in levetiracetam‐naïve patients. These findings build upon prior results, demonstrating that TMS‐based biomarkers are sensitive to levetiracetam's acute effects in epilepsy patients with MEP amplitude, LICI, and frontal beta/gamma power emerging as promising biomarkers, possible also for new ASM development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, The Netherlands.
- Leiden University Medical Center (LUMC), Leiden, The Netherlands.
- University of Twente & Medisch Spectrum Twente, Enschede, The Netherlands.
ORCID-Profile: Catherine M E de Cuba, Titia Q Ruijs, Annika A de Goede, Robert J Doll, Maria Juachon, Michel J A M van Putten, Geert Jan Groeneveld, Jules A A C Heuberger
Zitieren
APA
de Cuba, C. M. E., Ruijs, T. Q., de Goede, A. A., Doll, R. J., Juachon, M., van Putten, M. J. A. M., Groeneveld, G. J., & Heuberger, J. A. A. C. (2026). Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy. Clinical Pharmacology & Therapeutics, 120(3), 673-683. https://doi.org/10.1002/cpt.70327
Vancouver
de Cuba CME, Ruijs TQ, de Goede AA, Doll RJ, Juachon M, van Putten MJAM, et al. Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy. Clinical Pharmacology & Therapeutics. 2026;120(3):673-683. doi:10.1002/cpt.70327
BibTeX
@article{deCuba2026,
author = {de Cuba, Catherine M E and Ruijs, Titia Q and de Goede, Annika A and Doll, Robert J and Juachon, Maria and van Putten, Michel J A M and Groeneveld, Geert Jan and Heuberger, Jules A A C},
title = {Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {3},
pages = {673--683},
doi = {10.1002/cpt.70327}
}
EUVIMED